Cynthia Lynne Hartman, OTR/L, NP | |
6439 Garners Ferry Rd, Columbia, SC 29209-1638 | |
(803) 776-4000 | |
Not Available |
Full Name | Cynthia Lynne Hartman |
---|---|
Gender | Female |
Speciality | Nurse Practitioner - Family |
Location | 6439 Garners Ferry Rd, Columbia, South Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013951318 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 3089 (South Carolina) | Secondary |
363LF0000X | Nurse Practitioner - Family | 18101 (South Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Cynthia Lynne Hartman, OTR/L, NP 413 Woodlands Ridge Rd, Columbia, SC 29229-2304 Ph: (803) 419-5604 | Cynthia Lynne Hartman, OTR/L, NP 6439 Garners Ferry Rd, Columbia, SC 29209-1638 Ph: (803) 776-4000 |
News Archive
"In recent years, initiatives such as the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria have helped rein in some of the biggest scourges," Paul Farmer, co-founder of Partners in Health and chair of the Department of Global Health and Social Medicine at Harvard Medical School, writes in a Washington Post opinion piece.
One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.
Varian Medical Systems, Inc. today announced that its Board of Directors has authorized the company to repurchase an additional 8 million shares of its common stock during a period commencing immediately and extending through September 30, 2011. Stock repurchases will be made in the open market, in privately negotiated transactions, or in Rule 10b5-1 share repurchase plans, and may be made from time to time or in one or more larger blocks.
Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ISIS-BIIB4 Rx.
› Verified 4 days ago